S&P 500   3,784.71 (-0.29%)
DOW   30,889.07 (-0.33%)
QQQ   314.50 (+0.05%)
AAPL MSFT FB GOOGL AMZN TSLA NVDA BABA CGC GE
S&P 500   3,784.71 (-0.29%)
DOW   30,889.07 (-0.33%)
QQQ   314.50 (+0.05%)
AAPL MSFT FB GOOGL AMZN TSLA NVDA BABA CGC GE
S&P 500   3,784.71 (-0.29%)
DOW   30,889.07 (-0.33%)
QQQ   314.50 (+0.05%)
AAPL MSFT FB GOOGL AMZN TSLA NVDA BABA CGC GE
S&P 500   3,784.71 (-0.29%)
DOW   30,889.07 (-0.33%)
QQQ   314.50 (+0.05%)
AAPL MSFT FB GOOGL AMZN TSLA NVDA BABA CGC GE
Log in
NASDAQ:SGEN

Seagen Stock Forecast, Price & News

$180.10
+4.24 (+2.41 %)
(As of 01/15/2021 09:42 AM ET)
Add
Compare
Today's Range
$178.50
Now: $180.10
$181.00
50-Day Range
$165.45
MA: $182.85
$201.15
52-Week Range
$90.57
Now: $180.10
$213.94
Volume1,673 shs
Average Volume942,670 shs
Market Capitalization$32.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.13
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Seagen logo

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

421st out of 1,479 stocks

Biological Products, Except Diagnostic Industry

52nd out of 141 stocks

Analyst Opinion: 1.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Employees1,605

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share

Profitability

Net Income$-158,650,000.00

Miscellaneous

Market Cap$32.58 billion
Next Earnings Date2/11/2021 (Confirmed)
OptionableOptionable
$180.10
+4.24 (+2.41 %)
(As of 01/15/2021 09:42 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seagen (NASDAQ:SGEN) Frequently Asked Questions

How has Seagen's stock price been impacted by Coronavirus (COVID-19)?

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SGEN stock has increased by 68.3% and is now trading at $175.86.
View which stocks have been most impacted by COVID-19
.

Is Seagen a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 1 sell rating, 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Seagen?

Wall Street analysts have given Seagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Seagen
.

How can I listen to Seagen's earnings call?

Seagen will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its earnings results on Thursday, October, 29th. The biotechnology company reported $3.50 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $3.58. The biotechnology company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $486.67 million. Seagen had a negative net margin of 25.17% and a negative return on equity of 18.32%. The firm's revenue was up 397.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.55) earnings per share.
View Seagen's earnings history
.

What guidance has Seagen issued on next quarter's earnings?

Seagen updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.02-2.065 billion, compared to the consensus revenue estimate of $1.5 billion.

What price target have analysts set for SGEN?

17 brokers have issued twelve-month price objectives for Seagen's shares. Their forecasts range from $124.00 to $254.00. On average, they expect Seagen's stock price to reach $185.57 in the next twelve months. This suggests a possible upside of 5.5% from the stock's current price.
View analysts' price targets for Seagen
or view Wall Street analyst' top-rated stocks.

Who are some of Seagen's key competitors?

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 59, Pay $2.88M)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 59, Pay $1.11M)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 52, Pay $1M)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 63, Pay $1.74M)
  • Dr. Vaughn B. Himes, Chief Technical Officer (Age 59)
  • Peggy Pinkston, VP of Investor Relations
  • Ms. Nancy Whiting B.Sc., Pharm.D., Exec. VP of Corp. Strategy, Alliances & Communications
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. (Age 48)
  • Mr. Matt Skelton, VP of Marketing
  • Mr. Christopher P. Pawlowicz, Exec. VP of HR

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Gateway Investment Advisers LLC (0.01%), IFM Investors Pty Ltd (0.01%), Louisiana State Employees Retirement System (0.00%), Polianta Ltd (0.00%), Fulton Bank N.A. (0.00%) and OneAscent Financial Services LLC (0.00%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen
.

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Marc E Lippman, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Polianta Ltd, IFM Investors Pty Ltd, Diversified Trust Co, NuWave Investment Management LLC, OneAscent Financial Services LLC, Endurance Wealth Management Inc., and Fulton Bank N.A..
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $175.86.

How big of a company is Seagen?

Seagen has a market capitalization of $31.81 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seagen employs 1,605 workers across the globe.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.